We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-17.59%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.47B
AUM Growth
-$301M
Cap. Flow
+$247M
Cap. Flow %
16.82%
Top 10 Hldgs %
53.54%
Holding
70
New
19
Increased
8
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$84.4M
2
SAGE
Sage Therapeutics
SAGE
+$68.5M
3
BDTX icon
Black Diamond Therapeutics
BDTX
+$61.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$55.7M
5
AMRN
Amarin Corp
AMRN
+$37.4M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$82.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$29M
3
APLS
Apellis Pharmaceuticals
APLS
+$24.5M
4
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$23.5M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
51
DELISTED
Zogenix, Inc.
ZGNX
$4.33M 0.3%
+175,000
New +$6.37M
LJPC
52
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.74M 0.26%
890,700
+115,700
+15% +$731K
SLDB icon
53
Solid Biosciences
SLDB
$794M
$3.66M 0.25%
102,125
+33,334
+48% +$1.65M
VXX icon
54
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$154M
$3.47M 0.24%
1,172
-14,453
-92% -$23.5M
IDYA icon
55
IDEAYA Biosciences
IDYA
$3.42B
$3.15M 0.21%
764,252
– –
LSACU
56
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$3M 0.2%
+300,000
New +$2.97M
CBAY
57
DELISTED
Cymabay Therapeutics
CBAY
$2.96M 0.2%
2,000,000
– –
MREO
58
Mereo BioPharma
MREO
$54.7M
$2.56M 0.17%
+2,450,543
New +$4.24M
MIST icon
59
Milestone Pharmaceuticals
MIST
$138M
$2.03M 0.14%
1,102,194
– –
CLRB icon
60
Cellectar Biosciences
CLRB
$20.5M
$1.23M 0.08%
3,067
– –
BLPH
61
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.08M 0.07%
+98,809
New +$662K
ZYME icon
62
Zymeworks
ZYME
$1.61B
$887K 0.06%
+25,000
New +$1.02M
APLS
63
DELISTED
Apellis Pharmaceuticals
APLS
– –
-800,000
Closed -$24.5M
ARVN icon
64
Arvinas
ARVN
$518M
– –
-366,000
Closed -$15M
KALV
65
DELISTED
KalVista Pharmaceuticals
KALV
– –
-200,000
Closed -$3.56M
LXRX icon
66
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-2,775,000
Closed -$11.5M
SRPT icon
67
Sarepta Therapeutics
SRPT
$1.57B
– –
-225,000
Closed -$29M
ACHN
68
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-3,000,000
Closed -$18.2M
MDCO
69
CALL
DELISTED
Medicines Co
MDCO
– –
-100,000
Closed -$8.49M
MDCO
70
DELISTED
Medicines Co
MDCO
– –
-967,000
Closed -$82.1M
1 2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Boxer Capital held 70 positions worth $1.47B, down 17% from $1.77B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital deployed $247M of net new capital in Q1 2020, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Revolution Medicines: 3,049,764 shares worth $66.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, an estimated $23.5M trimmed.

  • Boxer Capital's largest Q1 2020 buy was Revolution Medicines: 3,049,764 shares worth $66.8M.
  • Boxer Capital added most to Sage Therapeutics in Q1 2020, an estimated $68.5M increase.
  • Boxer Capital's biggest Q1 2020 reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, cutting an estimated $23.5M.
  • Boxer Capital fully exited Medicines Co in Q1 2020, selling an estimated $82.1M.
  • Boxer Capital's ten largest holdings make up 54% of its $1.47B portfolio in Q1 2020.
  • Boxer Capital opened 19 new positions and closed 8 in Q1 2020.
  • Boxer Capital's portfolio value fell 17% quarter-over-quarter to $1.47B.

Based on Boxer Capital's 13F filing for Q1 2020, filed 15 May 2020.